ClinicalTrials.gg
CompletedNCT03990090Updated Nov 24, 2020

A Study of TG103 in Chinese Healthy Adult Subjects

A Phase 1 interventional study of TG103 and Placebo in Healthy, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-24.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purposes of this study are to determine:

  1. To assess the safety and tolerability of a single subcutaneous injection of different doses of TG103 in healthy Chinese adult subjects.
  2. The pharmacokinetic and pharmacodynamic characteristics of a single subcutaneous injection of different doses of TG103 in healthy Chinese adult subjects were assessed.
02

Conditions studied

  • Healthy

Keywords

  • TG103
  • Pharmacokinetic
  • Pharmacodynamic
  • Safety
  • Tolerability
03

In context

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old and ≤ 65 years old, male or female;
  • Medical history, physical examination, vital signs, 12-lead and laboratory examination, imaging examination (thyroid color Doppler ultrasound, abdominal color Doppler ultrasound, chest X-ray) in the normal range, or not in the normal range but the researchers consider they have no clinical significance;
  • The weighing no less than 50 kg in male subjects, and no less than 45 kg in female subjects , (BMI) between 18.9 and 27.9 kg/m2 (including boundary values)
  • Fasting blood glucose is between 3.9-6.1 mmol/L (excluding the boundary value), and is \<5.7%;
  • Subjects must use reliable methods of throughout the study period and avoid pregnancy in women or pregnancy in male subjects' partners at least 3 months after dosing;
  • The subject is fully aware of the test content and possible adverse reactions, and has the ability to communicate properly with the researcher while complying with the research requirements;
  • Voluntarily participate in the study and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Have a history of severe drug or food allergies, or who may be allergic to the test drug by the investigator;
  • Have serious history of pancreas, liver, kidney, gastrointestinal tract, cardiovascular, respiratory, hematological, central nervous system disease, etc.,or other important disease that have risks may endanger the safety of the subject or affect the absorption, metabolism, excretion, etc. of the study drug,or the investigator believes that the subject is not suitable for inclusion.
  • Have undergone major surgery within 3 months prior to the trial, or have experienced severe infection within 4 weeks prior to the trial;
  • Have diabetes, thyroid dysfunction or other endocrine diseases that may affect blood sugar metabolism;
  • Individual or family history of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia, or other genetic diseases that are susceptible to medullary medullary cancer;
  • Those with history of malignant tumors and mental illness, depression, anxiety, and epilepsy disease.
  • Drugs and drug abusers in the past three years;
  • Vaccination within 28 days prior to the trial or planned to be vaccinated within 1 week of receiving the study drug;
  • Has one or more positive tests in surface antigen, virus antibody, anti- antibody or anti- Treponema pallidum-specific antibody;
  • Lost more than 400 ml of blood due to blood donation or other reasons within 3 months before the test;
  • Apply a glucagon-like peptide-1(GLP-1 )analogue, a glucagon-like peptide-1(GLP-1 )receptor agonist, or any other incretin mimetic 1 month prior to the planned study drug, or other drugs that the investigator believes may affect the trial;
  • Those who took prescription or similar over-the-counter medications within 1 month prior to the trial to promote weight loss (eg, orlistat, sibutramine, rimonabant, phenylpropanolamine or chlorpheniramine) ;
  • Alcohol intake is more than 21 units of alcohol per week (male) / 14 units of alcohol per week(female) (1 unit ≈ 360mL beer, or 45mL spirits with 40% alcohol content, or 150mL wine) 3 months prior to the screening.
  • Regular consumption of caffeine more than 600 mg per day in the past 3 months (1 cup of coffee contains about 100 mg of caffeine, 1 cup of tea contains about 30 mg of caffeine, and 1 can of Coke contains about 20 mg of caffeine);
  • Those who have taken caffeinated products or drugs within 48 hours prior to the study;
  • Taken more than 5 cigarettes per day in the past 3 months;
  • The investigator considers that the subject's diet has a big difference in the ratio to normal protein, carbohydrate, and fat intake (eg, vegetarian)person;
  • There are symptoms such as dermatitis or skin abnormalities at the site of administration;
  • Participated in other drug studies within 3 months prior to the planned study drug or the time of the last test drug was less than 3 months prior to screening for the trial; or attempted to participate in other drug trials during the study;
  • Pregnancy, lactation or blood human chorionic gonadotropin(HCG) positive in pregnancy test;
  • Drug abuse screening, alcohol breath test positive;
  • Failure to ensure full participation in the trial;
  • Others who have been judged by the investigator that inappropriate to participate in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    TG103

    Escalating doses of TG103 administered subcutaneously (SC) once in healthy participants.

    Drug: TG103

  • Placebo comparator
    Placebo

    Placebo administered SC once in healthy participants.

    Drug: Placebo

Interventions

  • DrugTG103

    Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline through Day 28

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC)

    Area under the plasma concentration versus time curve (AUC) after administration of of TG103

    Time frame: 0,0.25,1,4,6,8,12,24,36,48,60,72,96,144,192,264,336,648h

  2. Peak Plasma Concentration (Cmax)

    Peak Plasma Concentration (Cmax) after administration of of TG103

    Time frame: 0,0.25,1,4,6,8,12,24,36,48,60,72,96,144,192,264,336,648h

  3. Time to maximum plasma concentration(Tmax)

    Time to maximum plasma concentration(Tmax)after administration of of TG103

    Time frame: 0,0.25,1,4,6,8,12,24,36,48,60,72,96,144,192,264,336,648hours

  4. Half time (t1/2)

    The half time of TG103 after administration are calculated.

    Time frame: 0,0.25,1,4,6,8,12,24,36,48,60,72,96,144,192,264,336,648hours

  5. Apparent clearance (CL/F)

    To assess the apparent clearance (CL/F) after administration of TG103

    Time frame: 0,0.25,1,4,6,8,12,24,36,48,60,72,96,144,192,264,336,648hours

  6. Fasting blood glucose

    Changes in Fasting blood glucose compared to baseline

    Time frame: 1,2,3,4,5,7days

  7. 2-hour postprandial blood glucose

    Changes in 2-hour postprandial blood glucose compared to baseline

    Time frame: 1,2,3,4,5,7days

  8. fasting insulin

    Changes in fasting insulin compared to baseline

    Time frame: -1,3days

  9. fasting glucagon

    Changes in fasting glucagon compared to baseline

    Time frame: -1,3days

07

Study locations

1 site
  • China-Japan Friendship Hospital
    Beijing, Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Nov 2020, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2019
First posted
Jun 18, 2019
StartActual
Jul 29, 2019
Primary completionActual
Nov 11, 2020
CompletionActual
Nov 11, 2020
Last update
Nov 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03990090
Responsible party
Sponsor
First posted
Jun 18, 2019
Start date
Jul 29, 2019
Primary completion
Nov 11, 2020
Completion
Nov 11, 2020
Last update
Nov 24, 2020

Study contacts

jintong li
principal investigator · China-Japan Friendship Hospital
li chen
principal investigator · China-Japan Friendship Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TG103

Start the discussion